357 related articles for article (PubMed ID: 34771535)
61. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
[TBL] [Abstract][Full Text] [Related]
62. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
63. Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.
Zhang X; Liu Y
CNS Neurol Disord Drug Targets; 2020; 19(3):165-173. PubMed ID: 32416683
[TBL] [Abstract][Full Text] [Related]
64. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
65. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
66. Relapsed Primary Central Nervous System Lymphoma: Current Advances.
Tao K; Wang X; Tian X
Front Oncol; 2021; 11():649789. PubMed ID: 33996566
[TBL] [Abstract][Full Text] [Related]
67. Advances in the treatment of newly diagnosed primary central nervous system lymphomas.
Qian L; Tomuleasa C; Florian IA; Shen J; Florian IS; Zdrenghea M; Dima D
Blood Res; 2017 Sep; 52(3):159-166. PubMed ID: 29043230
[TBL] [Abstract][Full Text] [Related]
68. Ibrutinib in B-cell lymphoma: single fighter might be enough?
Xue C; Wang X; Zhang L; Qu Q; Zhang Q; Jiang Y
Cancer Cell Int; 2020; 20():467. PubMed ID: 33005100
[TBL] [Abstract][Full Text] [Related]
69. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
70. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
71. [Treatment of Primary Central Nervous System Lymphoma: Standard Treatments According to the Japanese 2019 Guideline and Novel Treatments].
Sasaki N; Nagane M
Brain Nerve; 2021 Oct; 73(10):1107-1114. PubMed ID: 34615748
[TBL] [Abstract][Full Text] [Related]
72. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
73. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
74. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
75. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
76. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
77. Characteristics and Outcomes of Primary Central Nervous System Lymphoma: A Retrospective Study of 91 Cases in a Chinese Population.
Mao C; Chen F; Li Y; Jiang X; Liu S; Guo H; Huang L; Wei X; Liang Z; Li W; Tang K
World Neurosurg; 2019 Mar; 123():e15-e24. PubMed ID: 30326304
[TBL] [Abstract][Full Text] [Related]
78. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
79. Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells.
Wallace D; Reagan PM
Drugs; 2021 Apr; 81(6):669-684. PubMed ID: 33783717
[TBL] [Abstract][Full Text] [Related]
80. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]